ArticlebioRxiv : the preprint server for biology2025
Lack of synergy between AR targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
Nicole A Traphagen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.